Dynabol  (Methandrostenolone)

02 Details

 

 

Dynabol

 (Methandrostenolone)

 

Metandienone (pINN); Metandienon; Metandienona; Métandiénone; Metandienoni; Metandienonum; Methandrostenolone; NSC-42722.

17β-Hydroxy-17α-methylandrosta-1,4 dien-3-one. Метандиенон

 

C20H28O2 = 300.4.

 

CAS — 72-63-9.

 

ATC — A14AA03; D11AE01.

 

ATC Vet — QA14AA03; QD11AE01.

 

NOTE. The following terms have been used as ‘street names’ or slang names for various forms of methandienone: Iron Brew.

 

Pharmacopoeias. In Pol

 

Dynabol contains:100mg

• 100 mg / ml Methandrostenolone

 

Pharmacologic Category

Androgen

Dosing: Adult

 

100mg every 24 hours. Deep intramuscular injection

 

Dosing: Geriatric

Refer to adult dosing

Dosing: Pediatric

Has not been studied in pediatric population.

Dosing: Renal Impairment

No dosage adjustment provided in manufacturer’s labeling; use with caution due to propensity to cause edema.

Dosing: Hepatic Impairment

No dosage adjustment provided in manufacturer’s labeling; use with caution.

Use

 

Methandienone has anabolic and some androgenic properties. It has little progestogenic activity. Methandienone has been given orally as an anabolic drug.

 

Storage/Stability

Store in at room temperature in a dark and dry place.

Contraindications

Hypersensitivity to methandienone or any component of the formulation.

Warnings/Precautions

• Gynecomastia: May cause gynecomastia.
• Hepatic effects: Prolonged use and/or high doses may cause peliosis hepatis or liver cell tumors, which may not be apparent until liver failure or intra-abdominal hemorrhage develops. Discontinue in case of cholestatic hepatitis with jaundice or abnormal liver function tests.
• Venous thromboembolism: Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported with testosterone products. Evaluate patients with symptoms of pain, edema, warmth, and erythema in the lower extremity for DVT and those with acute shortness of breath for PE. Discontinue therapy if a venous thromboembolism is suspected.

Disease-related concerns:

• Breast cancer: Use with caution in patients with breast cancer; may cause hypercalcemia by stimulating osteolysis.
• Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention.
• Hepatic impairment: Use with caution in patients with hepatic impairment.

Pregnancy Risk Factor

X

Category X: Studies in animals or human beings have demonstrated fetal abnormalities, or there is evidence of fetal risk based on human experience, or both, and the risk of the use of the drug in pregnant women clearly outweighs any possible benefit. The drug is contraindicated in women who are or may become pregnant.

 

Pregnancy Considerations

Use is contraindicated in women who are or may become pregnant; masculinization of the fetus has been reported.

Lactation

Excretion in breast milk unknown/not recommended

Breast-Feeding Considerations

It is not known if methandienone is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.

Adverse Reactions

As with other 17α-alkylated compounds, methandienone is associated with hepatotoxicity and hepatic function should be monitored during therapy. It should probably be avoided in patients with hepatic impairment, and certainly if this is severe.

Frequency unknown.

Cardiovascular: Edema

Central nervous system: Depression, excitation, insomnia

Dermatologic: Acne (females and prepubertal males)

Also reported in females: Hirsutism, male-pattern baldness

Endocrine & metabolic: Electrolyte imbalances, glucose intolerance, gonadotropin secretion inhibited, gynecomastia, HDL decreased, LDL increased, libido changes

Also reported in females: Clitoral enlargement, menstrual irregularities

Genitourinary:

Prepubertal males: Increased or persistent erections, penile enlargement

Postpubertal males: Bladder irritation, epididymitis, impotence, oligospermia, priapism (chronic), testicular atrophy, testicular function inhibited

Hematologic: Prothrombin time increased, suppression of clotting factors

Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, bilirubin increased, cholestatic jaundice, hepatic necrosis (rare), hepatocellular neoplasms, peliosis hepatis (with long-term therapy)

Neuromuscular & skeletal: CPK increased, premature closure of epiphyses (in children)

Renal: Creatinine excretion increased

Metabolism/Transport Effects

 

None known.

 

Drug Interactions

Corticosteroids, Warfarin and Antidiabetic agents.

Test Interactions

 

May suppress factors II, V, VII, and X; may increase PT; may decrease thyroxine-binding globulin and radioactive iodine uptake

Monitoring Parameters

Liver function tests, cholesterol profile, hemoglobin/hematocrit; INR/PT in patients on anticoagulant therapy

Children: Radiographs of left wrist and hand every 6 months (to assess bone maturation)

Adult females: Signs of virilization (deepening voice, hirsutism, acne, clitoromegaly); urine and serum calcium in women with breast cancer.

Dosage Forms

Multi dosing vial: 100mg/10ml

Multi dosing vial: 100mg/1 ml

Anatomic Therapeutic Chemical (ATC) Classification

• A14AA03; D11AE01.

Mechanism of Action

Methandrostenolone is a 17alpha-alkylated anabolic-androgenic steroid and a synthetic derivative of testosterone with a similar mechanism of action to other anabolic steroids.

Pharmacodynamics/Kinetics

 

Methandrostenolone is a modified form of testosterone. The resulting steroid also has a much weaker relative binding affinity for the androgen receptor than testosterone, but at the same time displays a much longer half-life and lower affinity for serum-binding proteins in comparison. These features allow methandrostenolone to be a very potent anabolic steroid in spite of a weaker affinity for receptor binding.

Metabolism: hepatic

Half-life: 3-5 hours.